This product was always going to be a diagnosis tool for OSA given it covered all the AHI level range with AUC accuracy that of the laboratory and at-home OSA testing device but it's good to get confirmation from RAP. If it gets regulatory approval, I think this will be the 1st ever smart phone device used for OSA diagnosis, I know Google and RMD are in a JV to create a device similar to RAP's for nearly 2 years ago which they haven't managed to develop and the last quarter RMD reported making a $7M USD loss from this JV (watch this space, IMO) and I know Drowzle has a similar product but it doesn't cover all the AHI level, hence, they are marketing it as a screening tool.
BL might be right, we might see revenue from OSA before ResAppDx because the market is aware of OSA diagnosis, whereas, ResAppDx is a revolutionary biomarker technology requiring initial community "confident" which has stem to the FDA and why they are taking their time. I guess you can take this is a good sign because if they didn't think it will be beneficial and efficient for the community, they would have reject it by now after nearly 10 months of review. I honestly can't see why the community won't use it, even at $1 per cough from Google Play or App Store to your personal phone, that's cheap to get a piece of mind....hell, I'll even pay $10.
- Forums
- ASX - By Stock
- RAP
- 2020 The Year Of RAP
2020 The Year Of RAP, page-808
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 548 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
The Watchlist
SS1
SUN SILVER LIMITED
Gerard O'Donovan, Executive Director
Gerard O'Donovan
Executive Director
SPONSORED BY The Market Online